{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:29:17Z","timestamp":1791203357174,"version":"4.2.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1378\/chest.10-2077","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T01:55:30Z","timestamp":1307411730000},"page":"1480-1490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment"],"prefix":"10.1016","volume":"139","author":[{"given":"Mark P.","family":"Rogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stoltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.10-2077_bib1","series-title":"The Metabolic Basis of Inherited Disease","first-page":"2649","article-title":"Cystic fibrosis","author":"Boat","year":"1989"},{"issue":"5","key":"10.1378\/chest.10-2077_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/ajrccm.154.5.8912731","article-title":"Cystic fibrosis","volume":"154","author":"Davis","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"4922","key":"10.1378\/chest.10-2077_bib3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"9636","key":"10.1378\/chest.10-2077_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(08)61162-9","article-title":"Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis","volume":"372","author":"Quinton","year":"2008","journal-title":"Lancet"},{"key":"10.1378\/chest.10-2077_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1378\/chest.10-2077_bib6","first-page":"27","article-title":"Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism","volume":"232","author":"Gelman","year":"2003","journal-title":"Methods Mol Biol"},{"issue":"24","key":"10.1378\/chest.10-2077_bib7","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1002\/j.1460-2075.1994.tb06954.x","article-title":"Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP","volume":"13","author":"Lukacs","year":"1994","journal-title":"EMBO J"},{"issue":"41","key":"10.1378\/chest.10-2077_bib8","doi-asserted-by":"crossref","first-page":"25710","DOI":"10.1016\/S0021-9258(18)47306-1","article-title":"Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins","volume":"269","author":"Ward","year":"1994","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1378\/chest.10-2077_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin-proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"issue":"6","key":"10.1378\/chest.10-2077_bib10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/bi702209s","article-title":"Misfolding of the cystic fibrosis transmembrane conductance regulator and disease","volume":"47","author":"Cheung","year":"2008","journal-title":"Biochemistry"},{"issue":"1","key":"10.1378\/chest.10-2077_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/35050509","article-title":"The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation","volume":"3","author":"Meacham","year":"2001","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1378\/chest.10-2077_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1083\/jcb.200410065","article-title":"A foldable CFTRDeltaF508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase","volume":"167","author":"Younger","year":"2004","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1378\/chest.10-2077_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2006.06.041","article-title":"Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator","volume":"126","author":"Younger","year":"2006","journal-title":"Cell"},{"issue":"suppl 1","key":"10.1378\/chest.10-2077_bib14","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2091-8-S1-S11","article-title":"The role of the UPS in cystic fibrosis","volume":"8","author":"Turnbull","year":"2007","journal-title":"BMC Biochem"},{"issue":"14","key":"10.1378\/chest.10-2077_bib15","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1074\/jbc.M111958200","article-title":"A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator","volume":"277","author":"Gelman","year":"2002","journal-title":"J Biol Chem"},{"issue":"suppl 1","key":"10.1378\/chest.10-2077_bib16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2091-8-S1-S2","article-title":"The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias","volume":"8","author":"Davies","year":"2007","journal-title":"BMC Biochem"},{"issue":"18","key":"10.1378\/chest.10-2077_bib17","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.1074\/jbc.M512975200","article-title":"Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator","volume":"281","author":"Harada","year":"2006","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1378\/chest.10-2077_bib18","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1091\/mbc.e08-04-0357","article-title":"Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2","volume":"19","author":"Rosser","year":"2008","journal-title":"Mol Biol Cell"},{"issue":"9","key":"10.1378\/chest.10-2077_bib19","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1091\/mbc.e04-01-0024","article-title":"Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p\/EDEM and the Cdc48 protein complex in yeast","volume":"15","author":"Gnann","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"48","key":"10.1378\/chest.10-2077_bib20","doi-asserted-by":"crossref","first-page":"36856","DOI":"10.1074\/jbc.M607085200","article-title":"Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants","volume":"281","author":"Sun","year":"2006","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1378\/chest.10-2077_bib21","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1091\/mbc.e04-04-0293","article-title":"The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator","volume":"15","author":"Alberti","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"4","key":"10.1378\/chest.10-2077_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2006.09.043","article-title":"Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis","volume":"127","author":"Wang","year":"2006","journal-title":"Cell"},{"issue":"9","key":"10.1378\/chest.10-2077_bib23","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1096\/fj.07-105338","article-title":"Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia","volume":"22","author":"Sun","year":"2008","journal-title":"FASEB J"},{"issue":"6","key":"10.1378\/chest.10-2077_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1083\/jcb.200808124","article-title":"N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic","volume":"184","author":"Glozman","year":"2009","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1378\/chest.10-2077_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.200401035","article-title":"COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code","volume":"167","author":"Wang","year":"2004","journal-title":"J Cell Biol"},{"issue":"9","key":"10.1378\/chest.10-2077_bib26","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1091\/mbc.e07-01-0046","article-title":"Inhibiting endoplasmic reticulum (ER)-associated degradation of misfolded Yor1p does not permit ER export despite the presence of a diacidic sorting signal","volume":"18","author":"Pagant","year":"2007","journal-title":"Mol Biol Cell"},{"issue":"6","key":"10.1378\/chest.10-2077_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1091\/mbc.e09-12-1017","article-title":"Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis","volume":"21","author":"Koulov","year":"2010","journal-title":"Mol Biol Cell"},{"issue":"5865","key":"10.1378\/chest.10-2077_bib28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"issue":"6389","key":"10.1378\/chest.10-2077_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"issue":"4","key":"10.1378\/chest.10-2077_bib30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"issue":"29","key":"10.1378\/chest.10-2077_bib31","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J Biol Chem"},{"issue":"pt 2","key":"10.1378\/chest.10-2077_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1042\/bj3280353","article-title":"Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation","volume":"328","author":"Lukacs","year":"1997","journal-title":"Biochem J"},{"issue":"6","key":"10.1378\/chest.10-2077_bib33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1083\/jcb.200312018","article-title":"Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes","volume":"164","author":"Sharma","year":"2004","journal-title":"J Cell Biol"},{"issue":"5993","key":"10.1378\/chest.10-2077_bib34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"issue":"pt 17","key":"10.1378\/chest.10-2077_bib35","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1242\/jcs.028951","article-title":"Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator","volume":"121","author":"Chang","year":"2008","journal-title":"J Cell Sci"},{"issue":"44","key":"10.1378\/chest.10-2077_bib36","doi-asserted-by":"crossref","first-page":"36762","DOI":"10.1074\/jbc.M508944200","article-title":"The short apical membrane half-life of rescued DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of DeltaF508-CFTR in polarized human airway epithelial cells","volume":"280","author":"Swiatecka-Urban","year":"2005","journal-title":"J Biol Chem"},{"issue":"6648","key":"10.1378\/chest.10-2077_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/38514","article-title":"Stimulation of CFTR activity by its phosphorylated R domain","volume":"389","author":"Winter","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1378\/chest.10-2077_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1085\/jgp.200409076","article-title":"Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA","volume":"125","author":"Csan\u00e1dy","year":"2005","journal-title":"J Gen Physiol"},{"issue":"8","key":"10.1378\/chest.10-2077_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nsmb1278","article-title":"CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices","volume":"14","author":"Baker","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1378\/chest.10-2077_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0092-8674(91)90072-7","article-title":"Nucleoside triphosphates are required to open the CFTR chloride channel","volume":"67","author":"Anderson","year":"1991","journal-title":"Cell"},{"issue":"5077","key":"10.1378\/chest.10-2077_bib41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1126\/science.1382316","article-title":"Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains","volume":"257","author":"Anderson","year":"1992","journal-title":"Science"},{"issue":"2","key":"10.1378\/chest.10-2077_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.emboj.7600040","article-title":"Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator","volume":"23","author":"Lewis","year":"2004","journal-title":"EMBO J"},{"issue":"pt 5","key":"10.1378\/chest.10-2077_bib43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1042\/BST0331003","article-title":"Control of the CFTR channel's gates","volume":"33","author":"Vergani","year":"2005","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"10.1378\/chest.10-2077_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00424-006-0140-z","article-title":"CFTR (ABCC7) is a hydrolyzable-ligand-gated channel","volume":"453","author":"Aleksandrov","year":"2007","journal-title":"Pflugers Arch"},{"issue":"6","key":"10.1378\/chest.10-2077_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2014correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1378\/chest.10-2077_bib46","first-page":"354","article-title":"Worldwide survey of the delta F508 mutation\u2014report from the Cystic Fibrosis Genetic Analysis Consortium","volume":"47","year":"1990","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1378\/chest.10-2077_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1379\/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2","article-title":"Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein","volume":"1","author":"Brown","year":"1996","journal-title":"Cell Stress Chaperones"},{"issue":"9","key":"10.1378\/chest.10-2077_bib48","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1378\/chest.10-2077_bib49","first-page":"797","article-title":"A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction","volume":"3","author":"Dorin","year":"1996","journal-title":"Gene Ther"},{"issue":"1","key":"10.1378\/chest.10-2077_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng0992-21","article-title":"Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis","volume":"2","author":"Johnson","year":"1992","journal-title":"Nat Genet"},{"issue":"5","key":"10.1378\/chest.10-2077_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1378\/chest.10-2077_bib52","doi-asserted-by":"crossref","first-page":"L1123","DOI":"10.1152\/ajplung.00049.2005","article-title":"Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR","volume":"289","author":"Farmen","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1378\/chest.10-2077_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1378\/chest.10-2077_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/gte.1997.1.35","article-title":"Cystic fibrosis in Jews: frequency and mutation distribution","volume":"1","author":"Kerem","year":"1997","journal-title":"Genet Test"},{"issue":"7","key":"10.1378\/chest.10-2077_bib55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1378\/chest.10-2077_bib56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3476(95)70157-5","article-title":"Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations","volume":"127","author":"Wilschanski","year":"1995","journal-title":"J Pediatr"},{"issue":"10","key":"10.1378\/chest.10-2077_bib57","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1378\/chest.10-2077_bib58","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"10.1378\/chest.10-2077_bib59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)80890-9","article-title":"Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily","volume":"101","author":"Hopfner","year":"2000","journal-title":"Cell"},{"issue":"6416","key":"10.1378\/chest.10-2077_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form Cl-channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"issue":"3","key":"10.1378\/chest.10-2077_bib61","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ng1193-274","article-title":"A mutation in CFTR produces different phenotypes depending on chromosomal background","volume":"5","author":"Kiesewetter","year":"1993","journal-title":"Nat Genet"},{"issue":"3","key":"10.1378\/chest.10-2077_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ppul.20200","article-title":"Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy","volume":"40","author":"Kerem","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"22","key":"10.1378\/chest.10-2077_bib63","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM199011293232203","article-title":"The relation between genotype and phenotype in cystic fibrosis\u2014analysis of the most common mutation (delta F508)","volume":"323","author":"Kerem","year":"1990","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.10-2077_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1378\/chest.10-2077_bib65","first-page":"628","article-title":"Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation","volume":"52","author":"Sermet-Gaudelus","year":"2002","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1378\/chest.10-2077_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00442105","article-title":"Familial occurrence of meconium ileus","volume":"135","author":"Allan","year":"1981","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1378\/chest.10-2077_bib67","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.130.5.1441","article-title":"CFTR genotype as a predictor of prognosis in cystic fibrosis","volume":"130","author":"McKone","year":"2006","journal-title":"Chest"},{"issue":"1 suppl","key":"10.1378\/chest.10-2077_bib68","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.125.1_suppl.1S","article-title":"Cystic fibrosis adult care: consensus conference report","volume":"125","author":"Yankaskas","year":"2004","journal-title":"Chest"},{"issue":"10","key":"10.1378\/chest.10-2077_bib69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 suppl","key":"10.1378\/chest.10-2077_bib70","doi-asserted-by":"crossref","first-page":"124S","DOI":"10.1378\/chest.120.3_suppl.124S","article-title":"Gene therapy in cystic fibrosis","volume":"120","author":"Flotte","year":"2001","journal-title":"Chest"},{"issue":"9","key":"10.1378\/chest.10-2077_bib71","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/cbic.200700027","article-title":"Correctors of protein trafficking defects identified by a novel high-throughput screening assay","volume":"8","author":"Carlile","year":"2007","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1378\/chest.10-2077_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(01)02561-3","article-title":"Green fluorescent protein-based halide indicators with improved chloride and iodide affinities","volume":"499","author":"Galietta","year":"2001","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1378\/chest.10-2077_bib73","doi-asserted-by":"crossref","first-page":"C1734","DOI":"10.1152\/ajpcell.2001.281.5.C1734","article-title":"Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists","volume":"281","author":"Galietta","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"issue":"23","key":"10.1378\/chest.10-2077_bib74","doi-asserted-by":"crossref","first-page":"19723","DOI":"10.1074\/jbc.M101892200","article-title":"Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds","volume":"276","author":"Galietta","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1378\/chest.10-2077_bib75","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1074\/mcp.M800268-MCP200","article-title":"High-content functional screen to identify proteins that correct F508del-CFTR function","volume":"8","author":"Trzcinska-Daneluti","year":"2008","journal-title":"Mol Cell Proteomics"},{"issue":"7140","key":"10.1378\/chest.10-2077_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1378\/chest.10-2077_bib77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1073\/pnas.51.3.487","article-title":"Phenotypic repair by streptomycin of defective genotypes in E. coli","volume":"51","author":"Gorini","year":"1964","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1378\/chest.10-2077_bib78","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1378\/chest.10-2077_bib79","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"issue":"9","key":"10.1378\/chest.10-2077_bib80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr\u2212\/\u2212mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J Mol Med"},{"issue":"15","key":"10.1378\/chest.10-2077_bib81","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1378\/chest.10-2077_bib82","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1378\/chest.10-2077_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1165\/rcmb.2006-0173OC","article-title":"No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations","volume":"37","author":"Clancy","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1378\/chest.10-2077_bib84","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1378\/chest.10-2077_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1378\/chest.10-2077_bib86","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.0813345106","article-title":"Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression","volume":"106","author":"Auld","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1378\/chest.10-2077_bib87","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces CFTR protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"9640","key":"10.1378\/chest.10-2077_bib88","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"issue":"46","key":"10.1378\/chest.10-2077_bib89","doi-asserted-by":"crossref","first-page":"33247","DOI":"10.1074\/jbc.C700175200","article-title":"Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein","volume":"282","author":"Wang","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1378\/chest.10-2077_bib90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1074\/jbc.271.2.635","article-title":"Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation","volume":"271","author":"Sato","year":"1996","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1378\/chest.10-2077_bib91","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0021-9258(17)42090-4","article-title":"A set of endoplasmic reticulum proteins possessing properties of molecular chaperones includes Ca(2+)-binding proteins and members of the thioredoxin superfamily","volume":"269","author":"Nigam","year":"1994","journal-title":"J Biol Chem"},{"issue":"5670","key":"10.1378\/chest.10-2077_bib92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1093941","article-title":"Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects","volume":"304","author":"Egan","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1378\/chest.10-2077_bib93","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bbrc.2004.07.146","article-title":"Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells","volume":"322","author":"Dragomen","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1378\/chest.10-2077_bib94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2005-0286OC","article-title":"SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis","volume":"34","author":"Grubb","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"10.1378\/chest.10-2077_bib95","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI119788","article-title":"In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR","volume":"100","author":"Rubenstein","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1378\/chest.10-2077_bib96","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1378\/chest.10-2077_bib97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Mol Ther"},{"issue":"1","key":"10.1378\/chest.10-2077_bib98","doi-asserted-by":"crossref","first-page":"L58","DOI":"10.1152\/ajplung.2001.281.1.L58","article-title":"Induction of HSP70 promotes DeltaF508 CFTR trafficking","volume":"281","author":"Choo-Kang","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1378\/chest.10-2077_bib99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/thx.2003.019778","article-title":"Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis","volume":"60","author":"Dormer","year":"2005","journal-title":"Thorax"},{"issue":"3","key":"10.1378\/chest.10-2077_bib100","doi-asserted-by":"crossref","first-page":"L712","DOI":"10.1152\/ajplung.00314.2006","article-title":"Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis","volume":"293","author":"Poschet","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"10.1378\/chest.10-2077_bib101","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1124\/mol.107.040725","article-title":"Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect","volume":"73","author":"Robert","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1378\/chest.10-2077_bib102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/mp0500521","article-title":"Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound","volume":"2","author":"Loo","year":"2005","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1378\/chest.10-2077_bib103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/BJ20070478","article-title":"Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants","volume":"406","author":"Wang","year":"2007","journal-title":"Biochem J"},{"issue":"2","key":"10.1378\/chest.10-2077_bib104","first-page":"154","article-title":"VX-809, a CFTR corrector, increases the cell surface density of functional f508del-CFTR in pre-clinical models of cystic fibrosis","volume":"44","author":"Van Goor","year":"2009","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1378\/chest.10-2077_bib105","first-page":"228","article-title":"A phase II, randomized, placebo-controlled, clinical trial of four doses of VX-809 in CF patients homozygous for the F508del CFTR mutation","volume":"45","author":"Clancy","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1378\/chest.10-2077_bib106","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s004240050817","article-title":"Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms","volume":"437","author":"Al-Nakkash","year":"1999","journal-title":"Pflugers Arch"},{"issue":"3","key":"10.1378\/chest.10-2077_bib107","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1165\/rcmb.2002-0086OC","article-title":"Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids","volume":"31","author":"Lim","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1378\/chest.10-2077_bib108","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/mol.105.010959","article-title":"Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating","volume":"67","author":"Pedemonte","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1378\/chest.10-2077_bib109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1124\/jpet.106.104521","article-title":"Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels","volume":"319","author":"Noel","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"44","key":"10.1378\/chest.10-2077_bib110","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1378\/chest.10-2077_bib111","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.10-2077_bib112","first-page":"487","article-title":"Challenges of drug discovery for personalized medicine","volume":"8","author":"Jain","year":"2006","journal-title":"Curr Opin Mol Ther"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369211603097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369211603097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:25:45Z","timestamp":1757917545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369211603097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0012369211603097"],"URL":"https:\/\/doi.org\/10.1378\/chest.10-2077","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.10-2077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}